Table 2.
Clinical manifestations and inflammatory status prior to treatment.
| Variable | FMT Group (n = 46) |
Control Group (n = 40) |
t-Test Chi-Square Test |
|---|---|---|---|
| CRP pre-treatment (mean) | 46.8 mg/L | 56.2 mg/L | 0.18 |
| WBC count pre-treatment (mean) | 17,000 cells/mL | 16,850 cells/mL | 0.795 |
| Moderate abdominal pain pre-treatment | 26 (56.5%) | 18 (45%) | 0.28 |
| Severe abdominal pain pre-treatment | 20 (43.5%) | 22 (55%) | 0.28 |
| 3–5 stools/day pre-treatment | 28 (60.9%) | 24 (60%) | 0.93 |
| >5 stools/day pre-treatment | 18 (39.1%) | 16 (40%) | 0.93 |